Latest 10-Q quarterly reports

Syntec Optics Holdings, Inc. announced a 26% increase in Q2 2026 net sales to $8.3 million, returning to a net income of $0.3 million after a prior year loss, though year-to-date gross profit declined due to material cost increases.

Surgery Partners, Inc. announced its second quarter 2026 financial results, reporting a net loss attributable to the company of $15.0 million, a wider loss compared to the prior year's $2.5 million, alongside a 2.7% increase in total revenues.

Vaalco Energy Inc. (EGY) reported a significant increase in Q2 2026 revenue driven by higher commodity prices, though the six-month period showed a net loss due to substantial exploration costs.

Insight Molecular Diagnostics Inc. (IMDX) filed its Q2 2026 Form 10-Q, revealing a substantial decrease in net revenue and an increase in operating expenses, leading to a wider net loss.

P3 Health Partners Inc. filed its Q2 2026 Form 10-Q, revealing revenue growth but also substantial operating losses and significant financial challenges, including a going concern warning.

Compass Group Diversified Holdings LLC has amended its credit agreement, reducing revolving commitments and extending the maturity date, while also waiving certain milestone fees.

Consolidated Water Co. Ltd. reports Q2 2026 results with a new 25-year retail license in the Cayman Islands, while facing revenue declines in manufacturing and persistent receivables issues in The Bahamas.

Rapid7 reported a slight decrease in total revenue for the first half of 2026, alongside a notable increase in restructuring expenses related to workforce adjustments.

Metagenomi Therapeutics, Inc. filed its quarterly report for the period ending June 30, 2026, detailing ongoing research and development efforts, financial performance, and risk factors.

Oxford Square Capital Corp. filed its Form 10-Q for the quarter ended June 30, 2026, detailing a decrease in net asset value per share and mixed financial performance.

Allegiant Travel Company's Q2 2026 10-Q filing reveals substantial revenue increases and operational improvements, largely attributed to the recent acquisition of Sun Country Airlines, while navigating higher fuel costs and integration efforts.

Ceva Inc. reported a 13% year-over-year revenue increase to $29.0 million in Q2 2026, driven by strong licensing performance and growing royalty streams.

Entravision Communications Corporation reported a substantial increase in net revenue for the second quarter of 2026, driven by a significant expansion in its Advertising Technology & Services (ATS) segment.

Gaia, Inc. reported a 5.29% decrease in revenue for Q2 2026 compared to Q2 2025, alongside an increase in operating expenses and a net loss attributable to common shareholders of $3.0 million.

Vera Therapeutics announced its second-quarter 2026 financial results, highlighting increased operating expenses and continued net losses, while also noting the accelerated approval of its lead product, TRUTAKNA.

Olema Pharmaceuticals reported a significant increase in operating expenses, leading to a wider net loss for the period, despite continued progress in its clinical development programs.

ProKidney Corp. reported a net loss of $28.4 million for Q2 2026, with significant increases in R&D expenses and substantial doubt raised about its ability to continue as a going concern.

Quantum Computing Inc. (QUBT) reported substantial revenue growth in its Q2 2026 Form 10-Q, driven by recent acquisitions, but also disclosed significant operating losses and material weaknesses in internal controls.

Life360, Inc. announced a 38% year-over-year increase in total revenue for the second quarter of 2026, driven by significant growth in subscription and advertising segments.

UnitedHealth Group's Q2 2026 results show a significant increase in earnings and operating income, driven by strong performance across its segments, despite slight declines in membership.

Ardent Health reported a decrease in total revenue for the three months ended June 30, 2026, driven by lower net patient service revenue per adjusted admission, while operating expenses increased significantly.

Crescent Capital BDC, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing a decrease in investment income and an increase in non-accrual investments.

Axsome Therapeutics announced robust revenue increases for its key products AUVELITY, SUNOSI, and SYMBRAVO, but also reported substantial operating losses.

Orchestra BioMed Holdings, Inc. reported its Q2 2026 financial results, showing a significant increase in net loss driven by higher R&D expenses and substantial interest costs, though a gain from a strategic investment provided some offset.

Franklin Financial Services Corporation announced a significant increase in net income for the second quarter of 2026, driven by growth in net interest income and non-interest income, alongside robust asset and deposit expansion.

ProCap Acquisition Corp reports net income driven by interest earned on its trust account, while managing operational costs and awaiting a business combination.

Chiron Real Estate Inc. reported strong Q2 2026 results, driven by strategic acquisitions of seniors housing communities and a significant gain from the sale of investment properties.

Rocket Pharmaceuticals reports a significant financial boost from a $180 million Priority Review Voucher sale and FDA accelerated approval for its KRESLADI gene therapy, while advancing its cardiovascular pipeline.

TEN Holdings, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, revealing a 34.5% year-over-year revenue decrease and a widening net loss, while also disclosing ongoing government investigations.

Phunware, Inc. announced its second quarter 2026 financial results, showing a significant increase in net revenue driven by software subscriptions and services, but also a widening net loss and increased operating expenses.